Supplemental Table 2-4

We analyzed 3651 non-PCOS patients, and the clinical characteristics of the two groups are shown in Supplemental Table 2. There were statistically significant differences in BMI, gestational week, and total Gn dosage (P<0.05), but no statistically significant differences in serum AMH (P>0.05). Therefore, we separately performed PSM on age and age +BMI+total Gn dosage to analyse the relationship between serum AMH and gestational hypertension. In PSM, the clamp value was set at 0.2, and the ratio of patients with and without gestational hypertension was 1:4.
First, the clinical characteristics of the two groups after age matching is shown in Supplemental Table 3. Of these patients, 86 people were in the gestational hypertension group and 3,565 people were in the without-gestational hypertension group. Second, the clinical characteristics of the two groups after matching for age, BMI, and total Gn dose are shown in Supplemental Table 4, in which 85 people were in the gestational hypertension group and 334 people were in the without-gestational hypertension group.

本研究共分析3651例非多囊卵巢综合征（Polycystic Ovary Syndrome, PCOS）患者，两组患者的临床特征详见补充表2。两组在体重指数（Body Mass Index, BMI）、孕周及总促性腺激素（Gonadotropin, Gn）剂量方面的差异均具有统计学意义（P<0.05），而血清抗缪勒管激素（Anti-Müllerian Hormone, AMH）水平无统计学差异（P>0.05）。据此，本研究分别以年龄、年龄+BMI+总Gn剂量为匹配因素开展倾向得分匹配（Propensity Score Matching, PSM）分析，以探讨血清AMH与妊娠期高血压的关联。本次PSM分析中，卡尺值设定为0.2，妊娠期高血压患者与非妊娠期高血压患者的配比比例为1:4。
首先，年龄匹配后两组患者的临床特征详见补充表3。该亚组中，妊娠期高血压组共86例患者，非妊娠期高血压组共3565例患者。
其次，以年龄、BMI及总Gn剂量为匹配因素完成匹配后，两组患者的临床特征详见补充表4，其中妊娠期高血压组85例，非妊娠期高血压组334例。